# US 2012/0070891 A1 · Inhibition-based high-throughput screen strategy for cell clones

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0070891 A1
- Document ID: US20120070891A1
- Status: Published application
- Kind: A1
- Application number: 13/231,436
- Filed: 2011-09-13
- Published: 2012-03-22
- Earliest claimed: 2009-06-11
- Assignees: ScinoPharm Taiwan, Ltd.
- Inventors: Wei-Kuang LIU; Min-Pey Ding
- Web page: https://patentgrep.com/patent/US20120070891A1

## CPC

- C12N 15/1086: {Preparation or screening of expression libraries, e.g. reporter assays}
- C12N 15/85: for animal cells
- C40B 50/06: Biochemical methods, e.g. using enzymes or whole viable microorganisms
- C07K 2319/60: containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
- C12N 2840/203: having an IRES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A method for screening cells with high level expression of a target protein is disclosed. The method includes introducing into a plurality of host cells a DNA construct that encodes both a target protein and an inhibitor to an endogenous selectable marker in the host cells, screening host cells harboring the DNA construct for the expression of the endogenous selectable marker, and isolating cells with reduced expression of the selectable marker. Also disclosed is a DNA construct configured to express both the target protein and the inhibitor inside the host cell.

## Claims

### Claim at position 1

1-11. (canceled)

### Claim 12

An expression vector for high-throughput screening of cells harboring the expression vector, comprising:
a first nucleotide sequence encoding a target protein;
a second nucleotide sequence encoding an exogenous selection marker for a host cell;
a third nucleotide sequence encoding an inhibitor to an endogenous selection marker in the host cell; and
one or more regulatory elements that control the expression of the first, second and third nucleotide sequences in the host cell,
wherein the first nucleotide sequence is linked to the second nucleotide sequence by an internal ribosome entry site (IRES).

### Claim 13 (depends on 12)

The expression vector of claim 12, further comprising one or more anti-repressor elements.

### Claim 14 (depends on 13)

The expression vector of claim 13, wherein the one or more anti-repressor elements includes a partial mouse anti-repressor element 40.

### Claim 15 (depends on 12)

The expression vector of claim 12, wherein the inhibitor is an interfering RNA.

### Claim 16 (depends on 15)

The expression vector of claim 15, wherein the interfering RNA is a miR-30-based shRNA.

### Claim 17 (depends on 12)

The expression vector of claim 12, wherein the endogenous selection marker is a fluorescent protein.

### Claim 18 (depends on 17)

The expression vector of claim 17, wherein the fluorescent protein is green fluorescent protein.

### Claim 19 (depends on 12)

The expression vector of claim 12, wherein the exogenous selectable marker is dihydroforate reductase.

### Claim 20 (depends on 12)

The expression vector of claim 12, wherein the one or more regulatory elements include a CMV IE enhancer.
